Mario Alberto González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mario Alberto González has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Francisco J. Duque
Departamento de Medicina Animal, Hospital Clínico Veterinario, Universidad de Extremadura, 10003 Cáceres, Spain
3 shared publicationsNicolás R. Robles
Servicio de Nefrología, Hospital Universitario de Badajoz, Universidad de Extremadura, 06080 Badajoz, Spain
3 shared publicationsRafael Barrera-Chacón
Departamento de Medicina Animal, Hospital Clínico Veterinario, Universidad de Extremadura, 10003 Cáceres, Spain
3 shared publications- Beatriz Macías-García
MINVET Group, Departamento de Medicina Animal, Facultad de Veterinaria Universidad de Extremadura Cáceres Spain
2 shared publications Eva M. Pérez-Merino
Animal Medicine Department, University of Extremadura, 10003 Cáceres, Spain
2 shared publicationsFernando J. Peña
Animal Medicine Department, University of Extremadura, 10003 Cáceres, Spain; Laboratory of Equine Reproduction and Equine Spermatology, Veterinary Teaching Hospital, University of Extremadura, 10003 Cáceres, Spain
2 shared publications
Latest Publications
- Open Access
Evaluation of the Tolerability and Efficacy of Adjuvant Treatment with Adipose Mesenchymal Stem/Stromal Cells in Dogs with Kidney Disease Secondary to Leishmaniosis
The tolerability and efficacy of treatment with allogeneic adipose-derived mesenchymal stem cells (aAMSCs) were evaluated in dogs with kidney disease secondary to canine leishmaniosis (CanL). In this non-blinded, single-center, 3-month study, twenty dogs received either conventional treatment (CT; n = 10) or conventional treatment plus an intravenous dose of aAMSCs (CT + aAMSCs; n = 10). Efficacy was assessed at days 0, 30, and 90 using plasma and urinary biomarkers. In both groups (CT, n = 6; CT + aAMSCs, n = 7), glomerular filtration rate was estimated by scintigraphy, and urinary proteomics was performed. No serious adverse events were observed, although two dogs experienced transient gastrointestinal events. No significant between-group differences occurred in renal parameters at time points. Intragroup analyses showed significant reductions in uNGAL/c in both groups and UPCR only in CT + aAMSCs. Longitudinal mixed-effects analyses revealed no significant group × time interactions for any of the evaluated variables. Urinary proteomics identified four protein entries with higher abundance in the CT + aAMSCs group at T90, although UMAP showed no separation between groups. A single intravenous aAMSCs dose was well tolerated but provided no renal benefits over conventional treatment. Further studies should evaluate alternative dosing protocols.
Open AccessEvaluation of the Tolerability and Efficacy of Adjuvant Treatment with Adipose Mesenchymal Stem/Stromal Cells in Dogs with Kidney Disease Secondary to Leishmaniosis
The tolerability and efficacy of treatment with allogeneic adipose-derived mesenchymal stem cells (aAMSCs) were evaluated in dogs with kidney disease secondary to canine leishmaniosis (CanL). In this non-blinded, single-center, 3-month study, twenty dogs received either conventional treatment (CT; n = 10) or conventional treatment plus an intravenous dose of aAMSCs (CT + aAMSCs; n = 10). Efficacy was assessed at days 0, 30, and 90 using plasma and urinary biomarkers. In both groups (CT, n = 6; CT + aAMSCs, n = 7), glomerular filtration rate was estimated by scintigraphy, and urinary proteomics was performed. No serious adverse events were observed, although two dogs experienced transient gastrointestinal events. No significant between-group differences occurred in renal parameters at time points. Intragroup analyses showed significant reductions in uNGAL/c in both groups and UPCR only in CT + aAMSCs. Longitudinal mixed-effects analyses revealed no significant group × time interactions for any of the evaluated variables. Urinary proteomics identified four protein entries with higher abundance in the CT + aAMSCs group at T90, although UMAP showed no separation between groups. A single intravenous aAMSCs dose was well tolerated but provided no renal benefits over conventional treatment. Further studies should evaluate alternative dosing protocols.
- Open Access
- 22 February 2025
- Published by Elsevier in Research in Veterinary Science
- Vol. 187, 105588
New biomarkers and scintigraphic evaluation of renal function in dogs with canine leishmaniosis
- 22 February 2025
- Published by Elsevier in Research in Veterinary Science
- Vol. 187, 105588
Open AccessNew biomarkers and scintigraphic evaluation of renal function in dogs with canine leishmaniosis
- Open Access
- 22 June 2023
- Published by Elsevier in Research in Veterinary Science
- Vol. 161, 180-190
Proteomic research on new urinary biomarkers of renal disease in canine leishmaniosis: Survival and monitoring response to treatment
- 22 June 2023
- Published by Elsevier in Research in Veterinary Science
- Vol. 161, 180-190
Open AccessProteomic research on new urinary biomarkers of renal disease in canine leishmaniosis: Survival and monitoring response to treatment
- Open Access
- 25 June 2022
- Published by Elsevier in Research in Veterinary Science
- Vol. 149, 108-118
Urinary proteome of dogs with renal disease secondary to leishmaniosis
- 25 June 2022
- Published by Elsevier in Research in Veterinary Science
- Vol. 149, 108-118
Open AccessUrinary proteome of dogs with renal disease secondary to leishmaniosis
- Open Access
Effects of Sedation with Medetomidine and Dexmedetomidine on Doppler Measurements of Ovarian Artery Blood Flow in Bitches
The aim was to evaluate if medetomidine and dexmedetomidine affected arterial ovarian blood flow in dogs. The dogs were randomly assigned to two different groups. In Group 1, medetomidine (10 µg/kg) was administered intramuscularly and, in Group 2, dexmedetomidine (5 µg/kg) was used. After a preliminary exam, arterial blood pressure (BP) was measured and a duplex Doppler ultrasonographic examination of both ovarian arteries was performed. Twenty minutes after the administration of medetomidine or dexmedetomidine, BP and ovarian Doppler ultrasonography were repeated. High quality tracings of ovarian artery flow velocity were obtained in all dogs and Doppler parameters: Peak Systolic Velocity (PSV), End Diastolic Velocity (EDV) and Resistive Index (RI) were measured before and after drug administration in the left (LO) and right (RO) ovaries. PSV and EDV values decreased significantly after drug administration (p < 0.05) compared to the non-sedated values, but no differences were found between the LO and RO (p > 0.05). The RI was not affected by drugs administration in neither of the groups studied (p > 0.05). In conclusion, the administration of medetomidine or dexmedetomidine causes a decrease in blood flow velocity in the ovarian artery and may be a good choice to avoid excessive bleeding prior surgeries in which ovariectomy.
Open AccessEffects of Sedation with Medetomidine and Dexmedetomidine on Doppler Measurements of Ovarian Artery Blood Flow in Bitches
The aim was to evaluate if medetomidine and dexmedetomidine affected arterial ovarian blood flow in dogs. The dogs were randomly assigned to two different groups. In Group 1, medetomidine (10 µg/kg) was administered intramuscularly and, in Group 2, dexmedetomidine (5 µg/kg) was used. After a preliminary exam, arterial blood pressure (BP) was measured and a duplex Doppler ultrasonographic examination of both ovarian arteries was performed. Twenty minutes after the administration of medetomidine or dexmedetomidine, BP and ovarian Doppler ultrasonography were repeated. High quality tracings of ovarian artery flow velocity were obtained in all dogs and Doppler parameters: Peak Systolic Velocity (PSV), End Diastolic Velocity (EDV) and Resistive Index (RI) were measured before and after drug administration in the left (LO) and right (RO) ovaries. PSV and EDV values decreased significantly after drug administration (p < 0.05) compared to the non-sedated values, but no differences were found between the LO and RO (p > 0.05). The RI was not affected by drugs administration in neither of the groups studied (p > 0.05). In conclusion, the administration of medetomidine or dexmedetomidine causes a decrease in blood flow velocity in the ovarian artery and may be a good choice to avoid excessive bleeding prior surgeries in which ovariectomy.